REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS

Application Number	10/727,655				
Filing Date	December 05, 2003				
First Named Inventor	SZELENYI, ISTVAN, et al.				
Title	COMBINATIONS OF RETIGABINE AND SODIUM CHANNEL INHIBITORS OR SODIUM CHANNEL- INFLUENCING ACTIVE COMPOUNDS FOR TREATING PAINS				
Art Unit	1614				
Examiner Name	Kwon, Brian Yong S.				
Attorney Docket Number	081117-0126				

I hereby revoke :	all prev	ious powers of attorr	ney given in the	above-	identified ap	plication.	
1 —	orney is s	submitted herewith.					
OR						41552	
_		espondence address for the		pplication	n to:		
Firm or Individual N							
Address	ame						
City		-		State	T	- 13	Zip
Country							
Telephone	- 1			Email			
	ord of th	e entire interest. See 37 C R 3.73(b) is enclosed. (For					
SIGNATURE of Applicant or Assignee of Record							
Signature	Sil	len C Punt	ti-			Date Jun 18-08	
Name	Eileen	C. Pruette				Telephone 949	461-6219
Title and Company	VALEA	ive Vice President, Genera INT PHARMACEUTICALS	INTERNATIONAL				
NOTE. Signatures of all the signature is required, see	ne inventor below*.	s or assignees of record of the e	entire interest or their re	presentative	e(s) are required. S	ubmit multiple form	s if more than one
Total of		s are submitted.				-	

PLOSIENT (2014)
Approved for use through 07/31/2006. OMB 0551-0031
U.S. Platent and Transact Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless to deplays a valid Orter Inumber.

STATEMENT UNDER 37 CFR 3.73(B)						
Applicant/Patent Owner: Valeant Pharmaceuticals North America (formerly known as Xcel Pharmaceuticals, Inc.)						
Application No./Patent No.: 10/727,655 Filed/Issue Date: December 5, 2003						
Entitled: Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains						
Valeant Pharmaceuticals North America , a Concoration (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)						
states that it is: 1. It is assignee of the entire right, title, and interest; or						
an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is%						
in the patent application/patent identified above by virtue of either:						
A An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.						
OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:						
From: inventors To: VATRIS GMBH & CO. KG The document was recorded in the United States Patent and Trademark Office at Reel 015133, Frame_0421, or for which a copy thereof is attached.						
From: <u>vIATRIS GMBH & CO. KG</u> To: <u>XCEL PHARMACEUTICALS, INC.</u> The document was recorded in the United States Patent and Trademark Office at Reel_015212Frame_0443						
From: XCEL PHARMACEUTICALS, INC. To: VALEANT PHARMACEUTICALS NORTH AMERICA The document was recorded in the United States Patent and Trademark Office at Reel						
Additional documents in the chain of title are listed on a supplemental sheet,						
☑ Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]						
The undersigned (whose-title)'s supplied below) is additionized to act on behalf of the assignee.						
Robert Chai-On (7K), 545-0100						
Printed or Typed Name Vie Pesident, Ossistant Secretary Tile						

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain of ristin a benefit by the public which is to fits (end by the USFT) to process an application. Confidentially is governed by 53 U.S. C. 12 and 37 CFR 1.11 and 1.14. This collection is a startanted to last CFR industrial to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time by unrequire to complete the form and/or suggestions for reducing the stunder, should be sent to the Chief Information Officer, U.S. Palanti and Trademark Office, U.S. Department of Commence, O.D. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO 1143 ADDRESS. SEND TO: Commissioner for Patentia, F.O. Box 1450, Alexandria, VA 22313-1450, VA 22313-1450,